Leishmaniasis Treatment: Current Situation and Future Perspectives
A special issue of Tropical Medicine and Infectious Disease (ISSN 2414-6366). This special issue belongs to the section "Neglected and Emerging Tropical Diseases".
Deadline for manuscript submissions: closed (30 May 2023) | Viewed by 2862
Special Issue Editors
Interests: innate immunity; microRNAs; diabetes; leishmaniasis; host–pathogen interaction
Special Issue Information
Dear Colleagues,
Tropical Medicine and Infectious Diseases is pleased to annouce a Special Issue on “Leishmaniasis Treatment: Current Situation and Future Perspectives”, which will publish relevant studies reporting the current situation and future perspectives of leishmaniasis treatment through research that ranges from basic to translational.
Leishmaniasis is a complex of neglected tropical diseases that affects more than one billion people living in endemic areas. It is a vector-borne disease caused by protozoan parasites of the genus Leishmania, which comprises more than 20 species. Leishmaniasis is associated with three main clinical manifestations, including cutaneous, visceral and mucosal, each with a particular response to treatment.
Currently, the control of leishmaniasis relies on treatment with only three first-line therapies, and drug resistance limits their efficacy. This is one of the major challenges for the successful response to treatment and a patient’s full recovery. These limitations highlight the importance of developing new and innovative therapeutic strategies to efficiently control the disease.
Therefore, we welcome research groups and public health experts to submit their recent findings, either in the form of original research or a review focusing on different aspects of Leishmania research, such as: the current situation of treatment for leishmaniasis and recent advances in drug development (all clinical manifestations included); new and innovative strategies to treat leishmaniasis; therapy combinations; novel markers of prognosis and the response to treatment in leishmaniasis; mechanisms of drug resistance to leishmaniasis; immunotherapy; mechanisms of alternative drug-delivery systems and drug action to treat leishmaniasis; and future perspectives in leishmanisis treatment.
Dr. Natalia Machado Tavares
Dr. Cecília Beatriz Fiuza Favali
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Tropical Medicine and Infectious Disease is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- leishmaniasis
- treatment
- therapy
- Leishmania
- drug development
- tropical disease
